PMID: 11906645Mar 22, 2002Paper

High-dose peripheral blood stem cell infusion: a strategy to induce donor-specific hyporesponsiveness to allografts in pediatric renal transplant recipients

Pediatric Transplantation
H L TrivediKirtipal V Visana

Abstract

We designed and implemented a clinical trial to achieve zero-rejection status in pediatric renal allograft recipients, using granulocyte-macrophage colony-stimulating factor (GM-CSF)-stimulated peripheral blood stem cell (PBSC) infusion. We studied 44 consecutive patients: 24 volunteers in a treated group (Tn) and 20 in a control group (Cn). Both groups were comparable with respect to clinical and laboratory parameters. The Tn group had 70.8% one haplo-match donors and the Cn group had 80% one haplo-match donors. Patients in the Tn group received cyclosporin A (CsA) and 0.4 mg/kg body weight prednisolone as immunosuppressants; azathioprine was added for patients of the Cn group, who received 1 mg/kg body weight prednisolone together with CsA. Living-related donors (LRD) of patients in the Tn group received GM-CSF 450 microg on four consecutive days followed by leucopheresis and immediate transfusion of unmodified PBSC into the recipient. This procedure was repeated once/twice, with one portal and one/two systemic infusions. Our aim was to maximize the dose of PBSC. The total average dose was 22 x 10(8) cells/kg body weight. Lymphocyte cross-match (LCM) was performed before GM-CSF injection and after the last PBSC infusion. Foll...Continue Reading

References

Jun 1, 1986·World Journal of Surgery·O Salvatierra
Apr 1, 1993·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Y NakafusaM W Flye
Feb 13, 1999·Kidney International·L C RacusenY Yamaguchi
Mar 24, 2000·Pediatric Transplantation·K CransbergJ Nauta
Oct 3, 1953·Nature·R E BILLINGHAMP B MEDAWAR

❮ Previous
Next ❯

Citations

May 25, 2005·Pediatric Transplantation·Kiran K DhanireddyAllan D Kirk
Nov 4, 2008·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·K K DhanireddyA D Kirk
Jul 3, 2018·Frontiers in Medicine·Adriana Torres CrignaKaren Bieback
May 1, 2006·Expert Review of Clinical Immunology·Caroline BalletJean-Paul Soulillou
Mar 22, 2002·Pediatric Transplantation·Peter H Lapchak, David M Briscoe
Jan 26, 2005·Pediatric Transplantation·Kathryn J Tinckam, Mohamed H Sayegh
Jan 9, 2004·Pediatric Clinics of North America·Jonathan P PearlAllan D Kirk
Jun 23, 2011·Transplantation Proceedings·A V VanikarH L Trivedi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.